Meagan Montesion

22PUBLICATIONS
165CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 31, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

April A Apfelbaum, Eric Morin, Dominik Sturm

|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Jul 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.

Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar

|Jul 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.

Yoonha Choi, Neekesh V Dharia, Tomi Jun

|Sep 14, 2023
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content.

Radwa Sharaf, Dexter X Jin, John Grady

Pageof 4

Frequent Collaborators

8 joint publications

Lee Albacker

4 joint publications

Karthikeyan Murugesan

4 joint publications

Erik A Williams

4 joint publications

Garrett M Frampton